Barclays PLC Purchases 35,950 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Barclays PLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 312,560 shares of the biotechnology company's stock after purchasing an additional 35,950 shares during the quarter. Barclays PLC owned about 0.25% of Arrowhead Pharmaceuticals worth $5,876,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ARWR. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $38,000. Van ECK Associates Corp raised its position in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,250 shares in the last quarter. KBC Group NV lifted its stake in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $205,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock traded down $0.05 during trading hours on Tuesday, hitting $13.47. 1,112,802 shares of the company's stock traded hands, compared to its average volume of 1,444,018. The company has a fifty day simple moving average of $14.42 and a 200-day simple moving average of $18.38. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -2.61 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 50,800 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the completion of the transaction, the chief executive officer now directly owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 275,880 shares of company stock valued at $4,034,037 over the last ninety days. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Chardan Capital restated a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, B. Riley restated a "buy" rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.